Welcome to the Allergy Therapeutics Investor Relations Centre.

"We continue to execute our strategy to create significant value for our shareholders."

Manuel Llobet - CEO
Interim Results 2017

In the first half of the year, we continued to outperform the market and delivered an increase in revenue.

Annual Report 2018

2018 was a solid year for Allergy Therapeutics as we made important progress in key areas across the Company.

AT_Cover.jpg